Abstract
For a long time, nephrotoxicity has been definitively defined as renal injury or dysfunction that arises as a direct or indirect result of exposure to drugs and industrial or environmental chemicals. There are a number of inherent difficulties in diagnostic procedures for toxic nephropathy, which include the absence of standard diagnostic criteria and the inability to relate exposure to a given agent and the observed effect. Critically ill newborns represent a high risk population for developing toxic nephropathy because of incomplete maturation of the kidney; furthermore, they are often treated with a combination of various therapeutic agents, each of them potentially inducing renal tissue injury. Antibiotics, antifungals, and non-steroidal antiiflammatory drugs (NSAIDs) can induce nephrotoxic damage by several, concomitant mechanisms of action on different segments of the nephron. The most common clinical feature following a nephrotoxic effect is acute kidney injury (AKI) which, in turn, comprises a spectrum of severe tissue damages along the nephron, leading to an abrupt decline in renal function. Because early stages of toxic nephropathy are characterized by very few specific clinical signs and symptoms, there is the urgent need to investigate new biomarkers for predicting nephrotoxicity and localizing the injury to a specific nephron site, in order to reduce the risk of acute renal injury and/or acute tubular necrosis. The most promising biomarker for the early assessment of kidney injury and damage is neutrophil gelatinase-associated lipocalin (NGAL). NGAL can be easily measured in urine by an automated analytical method, allowing its clinical use in emergency likewise creatinine. Considerable expectations in terms of improvement of the management of newborns developing drug-induced nephropaties derive from the clinical application of metabolomics.
Keywords: Biomarkers, newborn, kidney, toxicity, uNGAL, metabolomics, nephrotoxicity, enviromental chemicals, nephron, AKI.
Current Medicinal Chemistry
Title:Nenatal Drug Induced Nephrotoxicity : Old and Next Generation Biomarkers for Early Detection and Management of Neonatal Drug-Induced Nephrotoxicity, with Special Emphasis on uNGAL and on Metabolomics
Volume: 19 Issue: 27
Author(s): V. Fanos, R. Antonucci, M. Zaffanello and M. Mussap
Affiliation:
Keywords: Biomarkers, newborn, kidney, toxicity, uNGAL, metabolomics, nephrotoxicity, enviromental chemicals, nephron, AKI.
Abstract: For a long time, nephrotoxicity has been definitively defined as renal injury or dysfunction that arises as a direct or indirect result of exposure to drugs and industrial or environmental chemicals. There are a number of inherent difficulties in diagnostic procedures for toxic nephropathy, which include the absence of standard diagnostic criteria and the inability to relate exposure to a given agent and the observed effect. Critically ill newborns represent a high risk population for developing toxic nephropathy because of incomplete maturation of the kidney; furthermore, they are often treated with a combination of various therapeutic agents, each of them potentially inducing renal tissue injury. Antibiotics, antifungals, and non-steroidal antiiflammatory drugs (NSAIDs) can induce nephrotoxic damage by several, concomitant mechanisms of action on different segments of the nephron. The most common clinical feature following a nephrotoxic effect is acute kidney injury (AKI) which, in turn, comprises a spectrum of severe tissue damages along the nephron, leading to an abrupt decline in renal function. Because early stages of toxic nephropathy are characterized by very few specific clinical signs and symptoms, there is the urgent need to investigate new biomarkers for predicting nephrotoxicity and localizing the injury to a specific nephron site, in order to reduce the risk of acute renal injury and/or acute tubular necrosis. The most promising biomarker for the early assessment of kidney injury and damage is neutrophil gelatinase-associated lipocalin (NGAL). NGAL can be easily measured in urine by an automated analytical method, allowing its clinical use in emergency likewise creatinine. Considerable expectations in terms of improvement of the management of newborns developing drug-induced nephropaties derive from the clinical application of metabolomics.
Export Options
About this article
Cite this article as:
Fanos V., Antonucci R., Zaffanello M. and Mussap M., Nenatal Drug Induced Nephrotoxicity : Old and Next Generation Biomarkers for Early Detection and Management of Neonatal Drug-Induced Nephrotoxicity, with Special Emphasis on uNGAL and on Metabolomics, Current Medicinal Chemistry 2012; 19 (27) . https://dx.doi.org/10.2174/092986712803306439
DOI https://dx.doi.org/10.2174/092986712803306439 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Therapy of Chronic Pain
Current Gene Therapy Increasing Access to HIV Testing for Women by Simplifying Pre- and Post-Test Counseling
Current Women`s Health Reviews A Review on Hematopoietic Stem Cell Treatment for Epilepsy
CNS & Neurological Disorders - Drug Targets Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism Microscopies at the Nanoscale for Nano-Scale Drug Delivery Systems
Current Drug Targets The Role of Vascular Factors in Late-Onset Sporadic Alzheimers Disease. Genetic and Molecular Aspects
Current Alzheimer Research Gene Therapy for Pituitary Tumors
Current Gene Therapy Ligand-modified Biopolymeric Nanoparticles as Efficient Tools for Targeted Cancer Therapy
Current Pharmaceutical Design Laboratory Diagnosis and Therapy of Invasive Fungal Infections
Current Drug Targets Inventions Designed to Enhance Drug Delivery Across Epithelial and Endothelial Cells Through the Paracellular Pathway
Recent Patents on Drug Delivery & Formulation Tuberculosis: Challenges to Improve the Treatment
Current Clinical Pharmacology Transforming Growth Factor-β Signaling in Motor Neuron Diseases
Current Molecular Medicine Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Current Medicinal Chemistry Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach
Current Pharmaceutical Design Itraconazole vs Fluconazole as a Primary Prophylaxis for Fungal Infections in HIV-Infected Patients in Thailand
Current HIV Research Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Microemulsion and Microemulsion-Based Gels for Topical Antifungal Therapy with Phytochemicals
Current Pharmaceutical Design The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors
Current Medicinal Chemistry Invasive Aspergillosis: New Insights into Disease, Diagnostic and Treatment
Current Pharmaceutical Design Clinical and Electroencephalographic Assessment of Cefepime During Treatment of Nosocomial Infections in Neurological Patients
Central Nervous System Agents in Medicinal Chemistry